Metformin Pill
Phase 2Small molecule
Metformin Pill is one of 57 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 2.
2
Indications
5
Total Trials
1
Active Trials
56
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
71 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Avandia
Jazz PharmaceuticalsApproved
Ozempic
Novo NordiskApproved
Daliresp
AstraZenecaApproved
Onglyza
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Evista
Eli LillyApproved
Glucophage
EMD SeronoApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Gynorest
SSolvay Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metformin1 trial
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
Recruiting·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 2·NCT06826092·110 enrolled
Polycystic Ovary Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metformin Pill. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- FFudan University